Bisphosphonates as a First-Line Treatment for Glucocorticoid-Induced Osteoporosis: Comment on the Article by Saag et al.

Détails

ID Serval
serval:BIB_F90DC7040A4D
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Lettre (letter): communication adressée à l'éditeur.
Collection
Publications
Titre
Bisphosphonates as a First-Line Treatment for Glucocorticoid-Induced Osteoporosis: Comment on the Article by Saag et al.
Périodique
Arthritis & rheumatology
Auteur(s)
Gonzalez-Rodriguez E., Aubry-Rozier B., Stoll D., Lamy O.
ISSN
2326-5205 (Electronic)
ISSN-L
2326-5191
Statut éditorial
Publié
Date de publication
10/2019
Peer-reviewed
Oui
Volume
71
Numéro
10
Pages
1770-1771
Langue
anglais
Notes
Publication types: Letter ; Comment
Publication Status: ppublish
Résumé
We read with interest the Article by KG. Saag and colleagues (1). This 24-month randomised trial demonstrated the efficacy and safety of denosumab compared with risedronate. The discussion does not take into account three major concerns regarding denosumab discontinuation (DD) that could modify the conclusions. This article is protected by copyright. All rights reserved.
Mots-clé
Bone Density Conservation Agents, Denosumab, Diphosphonates, Double-Blind Method, Glucocorticoids, Humans, Osteoporosis, Risedronic Acid
Pubmed
Web of science
Création de la notice
24/06/2019 16:09
Dernière modification de la notice
21/02/2020 6:19
Données d'usage